Device Trial Radar · NCT07797348
Prospective Post Market Clinical Trial for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH.
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Sep 1, 2028
Study completion Sep 1, 2029
Sponsor
- Lead sponsor
- Zenflow, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, open-label, parallel-group post-market clinical trial (PMCT). The overall objective of this PMCT is to compare the effectiveness, durability, and patient-centered outcomes of the Zenflow Spring System versus Tamsulosin in men who are not on active therapy with moderate to severe LUTS/BPH. Patients randomized to the Tamsulosin therapy arm will be allowed to crossover to receive treatment with the Zenflow Spring System after 1) their 3-month follow-up assessments are completed, 2) the patient's symptoms are confirmed to continue to warrant treatment; and 3) the patient continues to meet the study enrollment criteria.
Conditions
- Benign Prostatic Hyperplasia (BPH)
- Obstructive Lower Urinary Tract Symptoms (LUTS)
- Enlarged Prostate
Interventions
Zenflow Arm: Zenflow Spring System implant procedureDevice
The Zenflow Spring Implant is designed to be a permanent implant but can be repositioned or removed by the physician.
Medical Therapy TamsulosinDrug
Tamsulosin is a prescription medicine that relaxes the muscles around the prostate and bladder to help men with an enlarged prostate (BPH) urinate more easily
Primary outcomes
What the sponsor says the trial is designed to measure.
- International Prostate Symptom Score (IPSS) Total ScoreTime frame: Baseline (Day 1) to 3 months
- Observed rate of device-related or Tamsulosin-related serious adverse events (SAEs).Time frame: Baseline through study completion, an average of 1 year (Duration of study)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.